TW202440065A - 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法 - Google Patents

包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法 Download PDF

Info

Publication number
TW202440065A
TW202440065A TW112151142A TW112151142A TW202440065A TW 202440065 A TW202440065 A TW 202440065A TW 112151142 A TW112151142 A TW 112151142A TW 112151142 A TW112151142 A TW 112151142A TW 202440065 A TW202440065 A TW 202440065A
Authority
TW
Taiwan
Prior art keywords
solid dispersion
less
group
polymer
glass transition
Prior art date
Application number
TW112151142A
Other languages
English (en)
Chinese (zh)
Inventor
真貝太規
木下亮
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202440065A publication Critical patent/TW202440065A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112151142A 2022-12-28 2023-12-27 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法 TW202440065A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-211372 2022-12-28
JP2022211372 2022-12-28

Publications (1)

Publication Number Publication Date
TW202440065A true TW202440065A (zh) 2024-10-16

Family

ID=91717899

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112151142A TW202440065A (zh) 2022-12-28 2023-12-27 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法

Country Status (5)

Country Link
EP (1) EP4603546A1 (https=)
JP (1) JPWO2024143501A1 (https=)
CN (1) CN120418354A (https=)
TW (1) TW202440065A (https=)
WO (1) WO2024143501A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
HRP20041152B1 (hr) * 2002-05-07 2008-01-31 Ferring B.V. Farmaceutske formulacije
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US8372836B2 (en) 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
ES2525353T3 (es) 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
CA2892621C (en) 2012-12-10 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative
MX375448B (es) * 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
EP3153166B1 (en) 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
WO2016031651A1 (ja) * 2014-08-29 2016-03-03 花王株式会社 難溶解性ポリフェノール類を含有する固体分散体の製造方法
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
CA3095036A1 (en) * 2018-03-23 2019-09-26 Palatin Technologies, Inc. Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras

Also Published As

Publication number Publication date
CN120418354A (zh) 2025-08-01
WO2024143501A1 (ja) 2024-07-04
EP4603546A1 (en) 2025-08-20
JPWO2024143501A1 (https=) 2024-07-04

Similar Documents

Publication Publication Date Title
Mudie et al. A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets
US5900425A (en) Pharmaceutical preparations having controlled release of active compound and processes for their preparation
KR101737250B1 (ko) 개선된 생체이용률을 갖는 약학 조성물
KR101445398B1 (ko) 활성 성분을 신속 방출하는 고형 경구 투여용 제약 투여형태
RU2713428C1 (ru) Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат
JP2011530532A5 (ja) 固体分子分散物状のｈｃｖプロテアーゼインヒビターの薬学的処方物
CN101951889A (zh) 伊马替尼组合物
JP2006500349A (ja) 半順序薬剤およびポリマーの医薬組成物
TW201511780A (zh) 抗病毒化合物之固體分散調合物
CN101068550B (zh) 含有释放速度控制组分的羧酰胺人类免疫缺陷整合酶抑制剂药物制剂
JP2020529464A (ja) ３−フルオロ−４−［７−メトキシ−３−メチル−８−（１−メチル−１Ｈ−ピラゾール−４−イル）−２−オキソ−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル］−ベンゾニトリル含む医薬製剤
GB2393181A (en) Amorphous clopidogrel
CN101068533B (zh) 含有抗成核剂的药物组合物
TWI380829B (zh) 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法
JP2019019125A (ja) 口腔内崩壊錠及びその製造方法
WO2019192195A1 (zh) 含达比加群酯的药物组合物及其制备方法
KR102707060B1 (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
TW202440065A (zh) 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法
WO2009123169A1 (ja) アミド誘導体含有医薬組成物
Varshosaz et al. Enhancement of dissolution rate of fenofibrate by spray drying technique: Comparison of eudragit E-100, solutol® HS15 and hydroxypropyl cellulose as carriers
JPH08301789A (ja) 活性化合物の調節された放出性を有する製剤およびそれらの製造方法
US20210290541A1 (en) Solid dispersion of hydantoin derivative
US9775832B2 (en) Pharmaceutical composition for oral administration
WO2024080308A1 (ja) ペプチド、界面活性剤及びポリマーを含む組成物
US9211290B2 (en) Solid dispersions of amorphous paroxetine mesylate